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Development of effective vaccine candidates against tuberculosis (TB) is
currently the most important challenge in the prevention of this disease since the
BCG vaccine fails to guarantee a lifelong protection, while any other approved vaccine
with better efﬁciency is still absent. The protective effect of the recombinant fusion
protein CFP10–ESAT6–dIFN produced in a prokaryotic expression system (Escher-
ichia coli) has been assessed in a guinea pig model of acute TB. The tested antigen
comprises the Mycobacterium tuberculosis (Mtb) proteins ESAT6 and CFP10 as well
as modiﬁed human γ-interferon (dIFN) for boosting the immune response. Double
intradermal immunization of guinea pigs with the tested fusion protein (2 × 0.5 μg)
induces a protective effect against subsequent Mtb infection. The immunized guinea
pigs do not develop the symptoms of acute TB and their body weight gain was ﬁve
times more as compared with the non-immunized infected guinea pigs. The animal
group immunized with this dose of antigen displays the minimum morphological
changes in the internal organs and insigniﬁcant inﬂammatory lesions in the liver tissue,
which complies with a decrease in the bacterial load in the spleen and average Mtb
counts in macrophages.
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Introduction
The tuberculosis (TB) caused by Mycobacterium tuberculosis (Mtb) is
currently an extremely widespread disease in the world, with high morbidity and
mortality rates, despite the signiﬁcant advance in both medicine and vaccinology.
Mtb is an airborne pathogen; although only 5%–15% of the infected individuals
develop an active TB, the world cohort ofMtb carriers according to the WHO data
currently comprises two–three billion people [1].
The only TB vaccine currently available is bacillus Calmette–Guerin
(BCG), an attenuated Mycobacterium bovis strain, given soon after birth to
protect against severe forms of TB in childhood. However, BCG’s efﬁcacy
against pulmonary TB in adults is highly variable and depends on, among other
factors, ethnicity, and geographical location [2]. SinceMtb resides inside the cells,
the humoral immunity is insufﬁcient for the protection of the organism from
infection and development of active TB; thus, an efﬁcient T cell-mediated immune
response is necessary [3].
The intracellular Mtb localization and its ability to persist in the host body
for decades have made the design of new efﬁcient vaccines to replace BCG an
unexpectedly hard task. Although manifold new anti-TB vaccines are actively
designed all over the world, any vaccine exceeding BCG in its efﬁciency and
approved for clinical use is still absent. Currently, several new generation vaccines
designed using viral vectors as well as a number of subunit protein vaccines are at
different stages of clinical trials [4]. TheMtb-secreted proteins are regarded as the
promising component for preventive vaccines [5]. The proteins ESAT6 (6-kDa
early secretory antigenic target) and CFP10 (10-kDa culture ﬁltrate protein)
secreted at the early stage of the disease (early phase protein) are of special
interest. The protein ESAT6 and its chaperon CFP10 are highly immunogenic and
carry the epitopes recognized by T and B cells of TB patients [6, 7]. These proteins
are Mtb virulence factors; the corresponding genes are present only in the
pathogenic mycobacteria and are absent in BCG [8].
We have demonstrated earlier that the immunization of laboratory mice with
the recombinant proteins ESAT6 and CFP10 by either injection or oral adminis-
tration inhibits spleen lymphocyte function [9]. Moreover, both the recombinant
proteins ESAT6 and CFP10 separately and as a fusion protein are able to inhibit
macrophage functions reducing production of reactive oxygen species [10]. Since
the proteins ESAT6 and CFP10 display considerable immunogenicity and their
epitopes are recognized by T and B cells, they are promising as immunogens when
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constructing recombinant vaccines but in a modiﬁed form. The undesirable side
effects of the proteins ESAT6 and CFP10 can be reduced by the introduction of
additional components into the hybrid antigens containing these proteins. In
particular, administration of the recombinant fusion protein CFP10–ESAT6–dIFN
with the mouse IgG2a Fc fragment to laboratory mice increased the intensity of
Th-1 T-cell response accompanied by an increased IFN-γ, IL-12, and IL-4
production [11]. A statistically signiﬁcant increase in the immune response to
administration of the recombinant fusion protein CFP10–ESAT6–dIFN supple-
mented with modiﬁed human IFN-γ (dIFN, deltaferon) as compared with these
immunogens used alone has been demonstrated. Our experiments in mouse model
demonstrate that this protein has no cytotoxic effect on the blood mononuclear
cells and induces both the humoral and cell-mediated immune responses [12].
Thus, the considerable interest was to study the protective properties of the
recombinant fusion protein CFP10–ESAT6–dIFN in a guinea pig TB model.
The guinea pig TB model is widely used to assess the efﬁciency of new anti-
TB vaccine candidates [13]. Unlike the model that utilizes mice, which are apt to
develop a latent TB variant, the speciﬁc feature of the guinea pig model is that the
disease course is usually acute and has a lethal outcome. This paper summarizes
the results on the protective properties of the recombinant fusion protein CFP10–
ESAT6–dIFN produced in a prokaryotic expression system (Escherichia coli)
assessed in the guinea pig model of acute systemic TB.
Materials and Methods
Ethical statement
The guinea pig experiments were approved by the ethical committee with
the Ural Research Institute for Phthisiopulmonology, Ministry of Public Health of
the Russian Federation (record no. 36 of June 29, 2015).
Cloning and puriﬁcation of fusion protein
The target gene encoding the recombinant fusion protein CFP10–ESAT6–
dIFN was cloned from the plasmid pBI121–CFP10–ESAT6–dIFN [12] into the
expression vector pHis, carrying the sequence coding for a hexahistidine tract. The
BamHI and HindIII restriction endonuclease sites were introduced into the target
gene by PCR using the primers 5′-CCCGGATCCATGGCAGAGATGAAGACC-
GAT-3′ and 5′-CCCAAGCTTTTACTGGGATGCTCTTCGACC-3′, respectively
(restriction sites are italicized). E. coli strain BL21(DE3) transformed with
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the constructed plasmid pHis-chimera was used to obtain the recombinant
fusion protein CFP10–ESAT6–dIFN. The synthesis of the recombinant fusion
protein CFP10–ESAT6–dIFN was induced with 1 mM isopropyl β-D-1-
thiogalactopyranoside.
To isolate the recombinant fusion protein CFP10–ESAT6–dIFN, bacterial
cells were sonicated (Sonics Vibra Cell, USA). The sediment after centrifugation of
the bacterial lysate was dissolved in the buffer containing 100mMNaH2PO4, 10 mM
Tris–HCl, and 8 M urea (pH 8.0) and loaded onto the Ni-NTA agarose (Qiagen cat.
#30210) according to the manufacturer’s recommendations. The recombinant fusion
protein CFP10–ESAT6–dIFN was further puriﬁed by dialysis against phosphate
buffered saline (PBS) pH 7.4. Protein concentration was determined according to
Bradford [14]. The particle size in the recombinant fusion protein CFP10–ESAT6–
dIFN suspension was assessed in a transmitted light using an AxioScope2plus
(Zeiss) microscope equipped with an AxioCam HRc (Zeiss) camera.
The presence of the recombinant fusion protein CFP10–ESAT6–dIFN in
bacterial biomass was conﬁrmed by Western blot using Millipore nitrocellulose
membrane (0.45 μm), polyclonal serum of the rabbit immunized with ESAT6
protein, and peroxidase-conjugated goat anti-rabbit IgG (Jackson ImmunoResearch,
cat. #11-035-144) as primary and secondary antibodies. Pierce® ECL Western
Blotting Substrate (Thermo Scientiﬁc, cat. #32209, USA) and Kodak X-ray ﬁlm
were used for visualization. As a negative control, we used bovine serum albumin
(BSA).
The primary structure of the recombinant fusion protein CFP10–ESAT6–dIFN
was veriﬁed by mass spectrometry assay. After denaturing electrophoresis, the
corresponding protein fractions were cut off of the polyacrylamide gel with an
EXQuest spot cutter (BioRad, USA) and lysed with trypsin. The tryptic peptides were
puriﬁed and assayed using an Ultraﬂex III (Bruker, Germany) mass spectrometer.
Guinea pigs
Female guinea pigs were obtained from the Science and Production Associa-
tion for Medical and Immunological PreparationsMikrogen (Bashkortostan, Russia)
and kept under standard conditions with ad libitum access to food and water.
Immunization and infection of guinea pigs
The guinea pigs were immunized at an age of 2 months (weight: 300–320 g).
The recombinant fusion protein CFP10–ESAT6–dIFN suspension (0.5 ml in PBS
pH 7.4) was intradermally injected in the nuchal fold. Either single (1.0 or 4.0 μg
protein) or double (0.25, 0.5, 1.0, 2.0, or 4.0 μg protein with 14-day interval)
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immunization was used. In total, seven experimental groups immunized with
different doses of the recombinant fusion protein CFP10–ESAT6–dIFN, a com-
parative and a negative control groups (three guinea pigs in each group)
were assayed. The guinea pigs of the comparative group (Tub) received 2 TU
of tuberculin/puriﬁed protein derivate (PPD) (St. Petersburg Institute of
Vaccines and Sera and Plant for Production of Bacterial Preparations, Russia)
twice with a 14-day interval. The guinea pigs of negative control group (C−)
received PBS.
On day 28 after the ﬁrst immunization, the guinea pigs were subcutaneously
(right inguinal skin fold) infected with 0.2 ml of the suspension of the same 21-day
virulentMtbH37Rv culture containing 0.002 mg of the pathogen (2 × 105–2 × 106
CFU), according to the order of the Minister of Health of USSR No. 558 of June,
7, 1987. The infection intensity was assessed according to the change in guinea
pig’s body weight, state of the internal organs in autopsied guinea pigs (including
histological examination of the lungs, liver, and spleen), growth rate of the Mtb
from spleen homogenates on Lowenstein–Jensen (LJ) medium, and the number of
Mtb-infected macrophages isolated from the spleen of infected guinea pigs. The
guinea pigs were weighed ﬁve times starting from day 1 of infection (ﬁrst
weighing, day 28 after the ﬁrst immunization) to euthanasia (ﬁfth weighing, day
114 after infection and day 142 after the ﬁrst immunization).
Sample preparation
The guinea pigs were euthanized with Lysthenon (Nycomed Austria GmbH,
Austria) on day 142 after the ﬁrst immunization (day 114 after infection). The
macropathological changes in internal organs of guinea pigs were examined during
autopsy.
For histological examination of the lungs, liver, and spleen tissues, the
specimens were ﬁxed with 10% neutral formalin solution. The specimens were
processed in an STP 120-3 (Thermo Scientiﬁc, Germany) tissue processor using
isopropanol and mineral oil. The sections (4-μm thick) were stained with hematox-
ylin and eosin.
Macrophages were isolated from the spleen of infected guinea pigs under
sterile conditions. For this purpose, spleen samples were minced with scissors in
the RPMI 1640 medium (Biolot, Russia) supplemented with 2 mM glutamine
(Biolot) and 50 μg/ml gentamicin (Biolot). The cells were placed into 24 well
plates (Orange Scientiﬁc, Belgium) with cover glasses on the well bottom [3 × 105
cells/well in 0.5 ml of the RPMI 1640 medium with 10% fetal bovine serum
(Biolot), 2 mM glutamine, and 50 μg/ml gentamicin] [15]. The cells were ﬁxed
with 4% formalin after 16-h cultivation (+37 °C, 5% CO2) and stained according
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to Ziehl–Neelsen method with the corresponding straining kit (Pervaya Labor-
atornaya Companiya, Russia) according to the manufacturer’s protocol.
Microscopy
Cytological and histological slides were examined at the Shared Access
Center for Microscopy of Biological Objects with the Institute of Cytology and
Genetics (Siberian Branch, Russian Academy of Sciences, Novosibirsk, Russia)
using an AxioScope2plus (Zeiss) microscope equipped with an AxioCam HRc
(Zeiss) digital camera with the help of AxioVision 4.7 (Zeiss) software.
Bacterial enumeration
The bacterial load in the guinea pig spleens was assessed according to the
Mtb growth rate on dense LJ medium in two replicates. For preparation of culture
inoculum, spleen specimens were placed into 10% sodium phosphate (Na3PO4),
stirred for 10 min, and incubated for 18–20 h at +37 °C. The spleen specimens
were then minced, homogenized, and centrifuged for 15 min at 3,000 × g; the
sediment was neutralized with 1% citric acid solution. After washing with 15 ml of
distilled water, the sediment was again centrifuged (15 min, 3,000 × g) and
suspended in 1 ml of distilled water to plate 0.5 ml of the suspension onto dense
nutrient medium. The tubes were incubated at +37 °C for 10 weeks with
obligatory visual control on a weekly basis. The growth intensity was assessed
according to the number of colonies (CFU) grown from each sample.
Statistics
All data are given as the mean ± SD and ± SEM. Non-parametric Kruskal–
Wallis test with subsequent pairwise multiple comparison by Dunn’s test
(Statistica 5.5 software package) was used for analyzing the between-group
differences in body weight. The signiﬁcance level cut-off value (α) was 5%.
The differences in the relative counts of the infected macrophages in different
groups were analyzed by one-way analysis of variance.
Results
The recombinant fusion protein CFP10–ESAT6–dIFN used for immunization
Figure 1A shows the scheme of the gene encoding the recombinant fusion
protein CFP10–ESAT6–dIFN. This gene comprises four domains, namely,
his6, coding for polyhistidine tract; cfp10 and esat6, the genes coding for the
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corresponding Mtb-secreted proteins, CFP10 and ESAT6; and dIFN, the gene
coding for modiﬁed human IFN-γ (deltaferon). The nucleotide sequences
encoding the above-listed genes were supplemented with ggcgcgggg sequences,
encoding a Gly-Ala-Gly hinge to spatially separate the protein domains.
The recombinant fusion protein CFP10–ESAT6–dIFN comprised 356 amino
acids and its expected molecular weight was 39 kDa.
The recombinant fusion protein CFP10–ESAT6–dIFN produced in E. coli
was produced in an insoluble form with a yield of 3 mg/L bacterial culture. The
recombinant fusion protein CFP10–ESAT6–dIFN was puriﬁed and its presence
was conﬁrmed by Western blot assay (Figure 1B). The major band (arrow)
corresponded to the expected molecular weight of the recombinant fusion protein
CFP10–ESAT6–dIFN (39 kDa). The minor fractions with a larger molecular
weight (Figure 1B), which also bound polyclonal antibodies to ESAT6 protein, are
most likely the aggregates of the recombinant fusion protein CFP10–ESAT6–
dIFN and/or its parts.
The primary structure of the recombinant fusion protein CFP10–ESAT6–
dIFN was conﬁrmed by mass spectrometry assay. The suspension in PBS where
Figure 1. Chimeric gene cfp10–esat6–dIFN and the encoded protein. (A) Structure of the gene
encoding the recombinant fusion protein CFP10-ESAT6–dIFN; (B) Western blot pattern; and C–E:
the recombinant fusion protein CFP10-ESAT6–dIFN aggregates in the suspension for injection,
including (C) small, (D) medium-sized, and (E) large. his6, polyhistidine tract; cfp10 and esat6, the
genes coding for the corresponding Mtb proteins CFP10 and ESAT6; dIFN, the gene coding for
modiﬁed human IFN-γ (deltaferon); M, molecular weight markers; 1, negative control (BSA); 2, the
recombinant fusion protein CFP10-ESAT6–dIFN (arrow denotes the major fraction)
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the recombinant fusion protein CFP10–ESAT6–dIFNwas present as particles with
a size of 0.5–3.0 μm was used to immunize guinea pigs.
Protective effect of the recombinant fusion protein CFP10–ESAT6–dIFN
A protective effect of the recombinant fusion protein CFP10–ESAT6–dIFN
was assessed according to the change in the guinea pig’s body weight after Mtb
infection and the bacterial load. A large body size of guinea pigs allows for
estimation of the body weight loss, which is an adequate indicator for TB infection
development [16]. The change in body weight was assessed as the difference
between a next weighing and the initial value (on the day of infection with Mtb)
and the subsequent calculation of the mean weight change for each group. The
interval between weighing was 28 days. The experiment was completed on day
114 after infection, when the ﬁrst guinea pig died in the negative control group.
Figure 2A shows the dynamics of the changes in the body weight of guinea pigs.
The dynamics of weight change of an intact guinea pig not infected with Mtb
(dashed line, intact control) is plotted for comparison. Figure 2B shows the
changes in guinea pig’s body weight by the end of experiment (day 114 after
infection).
As compared with the intact control, the group of guinea pigs immunized
twice with 0.5 μg of the recombinant fusion protein CFP10–ESAT6–dIFN with an
interval of 14 days (Figure 2A, solid line with square dots) displayed a stable
Figure 2. Dynamics of guinea pig’s body weight after Mtb infection and the mean change in body
weight by the end of experiment. (A) The dynamics of changes in body weight over the infection
period (114 days) and (B) the mean change in body weight (±SD) on day 114 after infection.
Designations: 1–5, sequential number of measurements made with an interval of 28 days; C (intact),
intact control group (without immunization and Mtb infection); Tub, comparative group
(immunization with tuberculin); and C−, negative control group (without immunization), *p < 0.05
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increase in body weight during the entire experiment. Only a small weight loss
between measurements 4 and 5 was observed in this group. The guinea pigs
immunized with half dose (two immunizations of 0.25 μg each; Figure 2A, dashed
line with square dots) and double dose (two immunizations of 1.0 μg each;
Figure 2A, solid line with triangle dots) of the recombinant fusion protein CFP10–
ESAT6–dIFN also displayed a weight loss between the two last measurements.
Kruskal–Wallis analysis of the data on the increase in guinea pig’s body weight in
nine studied groups demonstrated a statistically signiﬁcant differences between the
groups (H= 16.5004, p = 0.0358). The statistically signiﬁcant differences
(Q= 3.268, Qcritical= 3.197, k= 9, α= 0.05) for the weight change in the exam-
ined animal groups relative to the negative control, group C− (without immuni-
zation), were detectable on day 114 after the infection only for the guinea pigs
immunized twice with the recombinant fusion protein CFP10–ESAT6–dIFN at a
dose of 0.5 μg (Figure 2B).
Figure 3 shows the content of Mtb in the spleen specimens of the infected
guinea pigs immunized with different doses of the recombinant fusion protein
CFP10–ESAT6–dIFN on LJ medium.
Note that a decrease in the bacterial load in the spleen of infected guinea pigs
relative to the unimmunized control (group C−) was observed in the groups
immunized with either the recombinant fusion protein CFP10–ESAT6–dIFN or
Figure 3. The content of Mtb in the spleen specimens of the infected guinea pigs immunized with
different doses of the recombinant fusion protein ESAT6–CFP10–dIFN. Designations: Tub,
comparative group (immunization with tuberculin) and C−, negative control (without
immunization), *p < 0.05
CFP10–ESAT6–DIFN PROTEIN PROTECTS AGAINST TB 47
Acta Microbiologica et Immunologica Hungarica 65, 2018
tuberculin. In a group immunized twice with 0.5 μg, the bacterial load in the spleen
was signiﬁcantly lower than in the comparison group (group Tub) and in groups
immunized twice with 4 μg and once with a dose of 1 μg.
Morphological manifestation of TB lesions in guinea pigs
All guinea pigs infected withMtb displayed the signs of TB infection in their
internal organs. Comparative examination of the visceral organs of the infected
guinea pigs demonstrated that in the group of guinea pigs immunized twice with
0.5 μg of the recombinant fusion protein CFP10–ESAT6–dIFN, the overall
morphological pattern was more consistent with that of the intact guinea pigs
than in the negative control (C− group, without immunization) and in the group
receiving tuberculin (Tub group) (Figure 4M–O).
Histological examination of the spleen of the group immunized twice with
0.5 μg of the recombinant fusion protein CFP10–ESAT6–dIFN demonstrated a
clear separation of the spleen tissue into white and red pulp. Follicles had a clear
structure, with pronounced germinal centers (Figure 4A). Single follicles tended to
merge. Follicles in Tub group were small and without pronounced germinal
centers (Figure 4B), while in the group C− follicles often did not have the clear
structure (Figure 4C). The ratio between white and red pulp was disrupted with a
predominance of white pulp (Figure 4B and C). In both forenamed groups,
ﬁbrosing zones and necrosis loci also were visualized, both in white and red pulp
with foci of hemorrhages.
According to the results of the histological examination, the lungs in the
group of guinea pigs immunized twice with 0.5 μg of the recombinant fusion
protein CFP10–ESAT6–dIFN had a normal structure on the whole (Figure 4D).
Nevertheless, there were visualized rare foci of mononuclear cell inﬁltration and
single granulomas consisting of macrophages, lymphocytes, ﬁbroblasts, and
single neutrophils with a predominant perivascular location (Figure 4G). Simu-
lataneously in the negative control group (C− group) as well as in the Tub group,
the presence of multiple granulomas characterized by a large number of neu-
trophils and macrophages in their composition (Figure 4E and F) and pneumonia
with large-scale necrosis and hemorrhage zones was documented with complete
disruption of the lung structure (Figure 4H and I).
Histological examination of the liver has demonstrated only a few inﬂam-
mation TB lesions represented by small areas with diffuse inﬁltration of mono-
nuclear cells in the group of guinea pigs immunized twice with 0.5 μg of the
recombinant fusion protein CFP10–ESAT6–dIFN (Figure 4J). In the liver of this
group, only small single granulomas were visualized. The presence of inﬁltration
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was recorded also in the triad area. Vessels were full-blooded without the tendency
to thrombosis. As for the remaining examined animal groups (Tub and
C− groups), the liver tissues were to a considerable degree replaced by
Figure 4. Histopathological (A–L) and comparative (M–O) examination of the visceral organs in
experimental and control groups on day 114 after infection with Mtb. (A–C) – spleen (follicles
designated by arrows); (D–I) – lungs; (J–O) – liver. (A) – follicles with a normal structure and
pronounced germinal centres; (B) – small follicles with not pronounced germinal centres,
predominance of white pulp; (C) – follicles with not pronounced structure, predominance of white
pulp; (D) – lung section with normal tissue structure; (E–G) – granulomas (arrows); (H, I) –
pneumonia (asterisks) and necrosis zone (red oval); (J) – mononuclear cell inﬁltration and weak
proliferation of bile ducts (arrow); (K) – granuloma with epithelioid cells (arrow); (L) – granuloma
(arrow) with necrosis zone (red circle); (M) – liver in the norm; (N, O) – liver with foci of caseous
necrosis. Tissue sections were stained by hematoxylin/eosin. Scale bars are 50 μm
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aggregations of granulomas. Granulomas were larger, with a tendency to associa-
tion and ﬁbrosing (Figure 4K). There were detected large-scale hemorrhage zones,
necrosis zones, and full-blooded sinusoids (Figure 4L). Vessels were full-blooded
with a tendency to thrombosis.
Mtb in guinea pig spleen macrophages
The isolated spleen macrophages after 16 h of cultivation in ex vivo culture
were stained according to Ziehl–Neelsen method to visualize acid-fastMtbwith an
undamaged cell wall. The average interval between the divisions ofMtb H37Rv is
approximately 20–24 h and macrophages were cultivated for 16 h; thus, it is
possible to regard that the Mtb counts in cells and the relative number of infected
cells did not change during ex vivo cultivation [15]. The Mtb in guinea pig
macrophages has a coccoid shape and a size of 0.5–1.5 μm. Spleen macrophages
contained both solitary mycobacterial cells (Figure 5B–E) and aggregates of Mtb,
formed as a result of division (Figure 5E and F).
Figure 6 shows the number of spleen macrophages infected byMtb in different
groups of experimental and control guinea pigs. The number of Mtb-infected
Figure 5. Macrophages from the spleen of Mtb-infected guinea pigs (staining by Ziehl–Neelsen
method). (A): Spleen, general view; (B–E): Macrophages containing solitary acid-fast Mtb (black
arrowheads); (E and F): Macrophages withMtb aggregates (black arrows). Scale bars are 10 μm each
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macrophages was less than 10% and 5% only in two experimental groups, namely
the groups where guinea pigs were twice immunized with the recombinant fusion
protein CFP10–ESAT6–dIFN at a dose of 2 × 0.25 and 2 × 0.5 μg, respectively.
The number of the infected spleen macrophages containing Mtb aggregates
did not differ between studied groups in a statistically signiﬁcant manner and
amounted to 40%–70% of all infected macrophages. The average number of Mtb
in infected macrophages is approximately the same in all groups of immunized
guinea pigs, varying from four to nine per macrophage. The distributions of spleen
macrophages according to the number of mycobacteria they contain are also
similar in the examined animal groups except for the negative control group
(group C−, without immunization), where some macrophages carried 50 and even
more mycobacteria.
Thus, the immunization with the recombinant fusion protein CFP10–
ESAT6–dIFN, at a dose of 2 × 0.25 or 2 × 0.5 μg led to a considerable decrease
in the number ofMtb-infected macrophages in the guinea pig spleen. Nonetheless,
the mycobacteria that survived in spleen macrophages retained their functional
status in the host cells, since the number of cells with reproducing Mtb is
comparable in all analyzed animal groups.
Discussion
The major principles in vaccine design have not changed much since the late
18th century. The empirical paradigm “isolate, inactivate, inject” even now
Figure 6. The number of Mtb-infected macrophages isolated from the spleen of guinea pigs from
different experimental, comparative group Tub (immunization with tuberculin) and C–, negative
control group (without immunization), expressed as a percentage of the total number of spleen
macrophages. Data are expressed as the means± SEM. *p < .05 [comparisons of data in
experimental groups 2 × 0.25 or 2 × 0.5 μg and negative control group C– (without immunization)]
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remains the most successful in the creation of most vaccines [17]. However, this
approach loses its effectiveness in the case of Mtb. The novel methodological
principles of next-generation vaccine design have established over the last decade
and offered the new opportunities in designing efﬁcient anti-Mtb vaccines. The
new paradigm consists in a comprehensive study of the pathogen and the
mechanisms of its interaction with the immune system as well as isolation of
its key antigens and only then in an informed construction of hybrid genetic
systems able to induce an efﬁcient immune response when introduced into the
body [4, 18, 19]. Such vaccines are safer, since they do not contain any live
mycobacteria or their lysates but rather carry the most immunogenic antigenic
epitopes of the pathogen.
Mtb is able to persist in the body of a carrier for a long time without causing
TB development [1]. Mycobacteria in the course of long-term coevolution with the
host have acquired speciﬁc mechanisms allowing them to enter macrophages and
survive there as well as to modulate the host immune system. Secretion of speciﬁc
bacterial proteins is what allows this pathogen to persist in macrophages and
modulate the immunity [20]; thus, many of these proteins can be used as antigens
for subunit recombinant vaccines.
Several hundreds of Mtb antigens promising for the construction of new
subunit vaccines are known now [21]. Most tested subunit vaccines contain the
proteins belonging to Mtb major secreted antigen complex (Ag85), in particular,
the proteins Ag85A and Ag85B, as well as an early secretory protein ESAT6 [22].
Two early secretory proteins CFP10 and ESAT6 (currently both proteins are
regarded as promising components for subunit recombinant vaccines) were used
for constructing the recombinant fusion antigen CFP10–ESAT6–dIFN. Both
CFP10 and ESAT6 proteins induce a pronounced delayed-type hypersensitivity
response [23] in guinea pigs, suggesting that they are strong T-cell antigens and
induce a pronounced T-cell response.
The proteins CFP10 and ESAT6 at a ratio of 1:1 interact to form a stable
complex with a more pronounced secondary structure as compared with each
protein alone [24]. The C-terminal region of CFP10 protein in this complex is free
and plays an important role in binding to the macrophage surface. The ESAT6:
CFP10 protein complex is able to enter the macrophage endoplasmic reticulum
and binds to β2-microglobulin, thereby decreasing the expression of MHC-I
molecules on the surface of infected cells and inhibiting the presentation of MHC-
I-restricted antigens [25]. The ESAT6 protein is the major player in this effect of
the ESAT6:CFP10 protein complex. Since the C-terminal region of ESAT6
molecule in this complex is inaccessible for binding to β2-microglobulin, this
protein will not interfere with the presentation of MHC-I-restricted epitopes (the
accessibility of ESAT6 C-terminal region end is essential for this effect [25]).
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The recombinant fusion protein CFP10–ESAT6–dIFN produced in a bacte-
rial expression system (E. coli) is insoluble in buffer aqueous solutions. After the
isolation and puriﬁcation procedures, the recombinant fusion protein CFP10–
ESAT6–dIFN in PBS was represented by the particles with a size of 0.5–3.0 μm.
According to Champion et al. [26], this is the optimal size range for macrophages
to engulf the particles. Thus, it is no need in additionally using any absorption-
promoting adjuvants, such as, for example, involving aluminium compounds [27],
to enhance efﬁcient phagocytosis of the recombinant fusion protein CFP10–
ESAT6–dIFN. The aluminium-containing adjuvants are widely used in medicine,
but their application has certain limitations because of Th2 polarization of the
immune response, undesirable in the case of TB [28].
When designing a vaccine, it is necessary to consider that a considerable part
of the population is already infected with Mtb; thus, the vaccination has to solve
this problem as well. Therefore, the models of primary infection with acute
manifestation, latent TB, and reactivation of former TB are used for assessing the
protective effect and immunogenicity of TB vaccine candidates. The guinea pig
model of primary TB infection is illustrative for vaccine protective effect, because
the induced disease proceeds in an acute manner with pronounced changes in the
morphology of affected organs (these model guinea pigs usually do not develop a
latent TB disease [16]). Note that we have utilized an original model with
subcutaneous infection, which induces a generalized TB form rather than primary
lung TB, developing in the case of an inhalational infection. We have earlier
demonstrated that the recombinant fusion protein containing the Mtb antigens
ESAT6 and CFP10 together with modiﬁed human IFN-γ (deltaferon) induces
production of speciﬁc antibodies and antigen-speciﬁc proliferation of the
peripheral blood mononuclear cells in the guinea pig immunized by injection or
orally [12].
This work demonstrates that the tested recombinant fusion protein CFP10–
ESAT6–dIFN is capable of protecting the guinea pigs in the model of acute
systemic TB. It is shown that double intradermal administration of the recombi-
nant fusion protein CFP10–ESAT6–dIFN (2 × 0.5 μg) induced the optimal
protective effect. The guinea pigs immunized with this dose according to this
scheme displayed no symptoms of acute TB and gained body weight better as
compared with the unimmunized guinea pigs in a statistically signiﬁcant manner.
Autopsy demonstrates that the guinea pigs of this experimental group have
developed the minimal number of morphological changes in their internal organs
and insigniﬁcant inﬂammatory lesions in their lung, liver, and spleen tissues.
The protective effect of the recombinant fusion protein CFP10–ESAT6–
dIFN againstMtb infection was signiﬁcantly lower when the guinea pigs received
(once or twice) other doses of this antigen. Presumably, a decrease in the
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protective effect of the studied recombinant fusion protein CFP10–ESAT6–dIFN
is associated with the ability of this protein it contains to suppress mononuclear
cells [10]. The ability of CFP10 and ESAT6 proteins to inhibit the response of
mouse spleen lymphocytes to non-speciﬁc stimulation with phytohaemagglutinin
was described earlier [9].
Our results suggest that an important factor in guinea pig immunization is an
adequate dose of the introduced antigen; in this case, the optimal dose was 0.5 μg
and the recombinant fusion protein CFP10–ESAT6–dIFN intradermally injected
twice (2 × 0.5 μg). Another administration scheme or overdosage of the
recombinant fusion protein CFP10–ESAT6–dIFN signiﬁcantly decreased the
protective effect; the mechanism of this decrease is vague.
Immunization of mice with the recombinant fusion protein CFP10–ESAT6–
dIFN was shown to increase the T-cell immune response, and the effect was even
more pronounced when supplementing the fusion protein with Fc receptor [11].
The protective effect of a recombinant protein comprising two Mtb antigens,
ESAT6 and Ag85B, was demonstrated in a guinea pig model [29]. Note that the
protective effect of the fused protein ESAT6–Ag85B was higher as compared with
the effects of each protein alone but still yielded to the protective effect caused in
guinea pigs by BCG immunization. The experimental data [29] demonstrate that
the protection againstMtb provided by the recombinant fusion protein comprising
these two antigens (ESAT6 and Ag85B) was close to that of BCG.
In our experiment, both experimental and control guinea pigs were
euthanized and autopsied on day 114 after the infection with Mtb. Further
examination demonstrated that the experimental guinea pigs immunized
twice with the recombinant fusion protein CFP10–ESAT6–dIFN at a dose of
0.5 μg (2 × 0.5 μg) developed only insigniﬁcant signs of TB infection. It should
be emphasized that the mycobacteria load of the spleen tissues in this particular
experimental group decreased at least 30-fold as compared with the negative
control. Our results considerably exceed the effect of vaccination with the
recombinant protein MTB41 [30]. The mycobacteria load in the mice vaccinated
with the fusion protein ESAT6–Ag85B–MPT64(190–198)–Mtb8.4–Rv2626c and
subsequently infected decreased maximum 18-fold [31].
When entering the body,Mtb interacts with the host immune system through
various cell types, including macrophages, dendritic cells, alveolar epithelial cells,
neutrophils, and natural killer cells. These cells are focused on not only Mtb
detection and destruction, but also triggering of the adaptive or speciﬁc host
immune response; yet Mtb during their evolution has developed rather numerous
strategies to escape the host defense mechanisms. For example, a macrophage
actively phagocytizes Mtb, but the bacterium prevents the fusion of a phagosome
and lysosome and maturation of phagolysosome, providing its own long-term
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existence within the macrophage. It is possible to assess the degree of stability
(“preparedness”) of the body to control this infection considering these speciﬁc
features in the interaction between macrophage and Mtb. The Mtb counts in the
spleen macrophages of different groups of experimental guinea pigs demonstrate
that the number of Mtb-infected macrophages was signiﬁcantly lower in two
animal groups as compared not only with the control (immunization with
tuberculin and no immunization at all), but also with the other experimental
groups immunized with higher doses of the recombinant fusion protein CFP10–
ESAT6–dIFN; these groups are the groups immunized twice with the recombinant
fusion protein CFP10–ESAT6–dIFN at a dose of 0.25 and 0.5 μg protein (2 × 0.25
and 2 × 0. 5 μg). The average number of infected spleen macrophages in the
guinea pigs that received a dose of 2 × 0.5 μg the recombinant fusion protein
CFP10–ESAT6–dIFN was almost 10-fold lower as compared with the negative
control (without immunization) and the proportion of macrophages with actively
proliferating Mtb decreased twofold, respectively. Our results conﬁrm a decrease
in the bacterial load in the guinea pigs of these groups.
Thus, we have demonstrated that the tested recombinant fusion protein
CFP10–ESAT6–dIFN has a pronounced protective effect in the guinea pig model
of acute TB with a trend to exceed the effect of tuberculin, used as comparative
control. It is of interest to further study the parameters of the T-cell response
induced by the recombinant fusion protein CFP10–ESAT6–dIFN and to charac-
terize the role of modiﬁed human IFN- γ (deltaferon) within this fusion protein.
Acknowledgements
The work was supported by the Program of Siberian Branch of Russian
Academy of Science “Genetic bases of biotechnology and bioinformatics,” Project
0324-2018-0017.
Conﬂict of Interest
The authors declare no conﬂict of interest regarding the publication of this
article.
References
1. World Health Organization [WHO]: WHO Global tuberculosis report 2016 (2016).
Available at http://www.who.int/tb/publications/global_report/en/
CFP10–ESAT6–DIFN PROTEIN PROTECTS AGAINST TB 55
Acta Microbiologica et Immunologica Hungarica 65, 2018
2. Mangtani, P., Abubakar, I., Ariti, C., Beynon, R., Pimpin, L., Fine, P. E., Rodrigues, L. C.,
Smith, P. G., Lipman, M., Whiting, P. F., Sterne, J. A.: Protection by BCG against
tuberculosis: A systematic review of randomised controlled trials. Clin Infect Dis 58,
470–480 (2013). Available at https://academic.oup.com/cid/article/58/4/470/347668/
Protection-by-BCG-Vaccine-Against-Tuberculosis-A
3. Kaufmann, S. H. E.: Tuberculosis vaccines: Time to think about the next generation. Semin
Immunol 25, 172–181 (2013). Available at http://www.sciencedirect.com/science/article/
pii/S1044532313000225
4. Evans, T. G., Schrager, L., Thole, J.: Status of vaccine research and development of
vaccines for tuberculosis. Vaccine 34, 2911–2914 (2016). Available at http://www.
sciencedirect.com/science/article/pii/S0264410X16002929
5. Andersen, P.: Effective vaccination of mice against Mycobacterium tuberculosis infection
with a soluble mixture of secreted mycobacterial proteins. Infect Immun 62, 2536–2544
(1994). Available at http://iai.asm.org/content/62/6/2536.short
6. Yu, F., Wang, J., Dou, J., Yang, H., He, X., Xu, W., Zhang, Y., Hu, K., Gu, N.:
Nanoparticle-based adjuvant for enhanced protective efﬁcacy of DNA vaccine Ag85A-
ESAT-6-IL-21 against Mycobacterium tuberculosis infection. Nanomed Nanotechnol Biol
Med 8, 1337–1344 (2012). Available at http://www.sciencedirect.com/science/article/pii/
S1549963412000913
7. Klucar, P., Barnes, P. F., Kong, Y., Howard, S. T., Pang, X., Huang, F. F., Tvinnereim,
A. R., Samten, B., Shams, H.: Vaccination strategies to enhance local immunity and
protection against Mycobacterium tuberculosis. Vaccine 27, 1816–1824 (2009). Available
at http://www.sciencedirect.com/science/article/pii/S0264410X0900156X
8. Welin, A., Björnsdottir, H., Winther, M., Christenson, K., Oprea, T., Karlsson, A.,
Forsman, H., Dahlgren, C., Bylund, J.: CFP-10 from Mycobacterium tuberculosis
selectively activates human neutrophils through a pertussis toxin-sensitive chemotactic
receptor. Infect Immun 83, 205–213 (2015). Available at http://iai.asm.org/content/
83/1/205.short
9. Uvarova, E. A., Belavin, P. A., Permyakova, N. V., Zagorskaya, A. A., Nosareva, O. V.,
Kakimzhanova, A. A., Deineko, E. V.: Oral immunogenicity of plant-madeMycobacterium
tuberculosis ESAT6 and CFP10. Biomed Res Int 2013, 316304 (2013). Available at https://
www.hindawi.com/journals/bmri/2013/316304/
10. Seghatoleslam, A., Hemmati, M., Ebadat, S., Movahedi, B., Mostafavi-Pour, Z.: Macro-
phage immune response suppression by recombinantMycobacterium tuberculosis antigens,
the ESAT-6, CFP-10, and ESAT-6/CFP-10 fusion proteins. Iran J Med Sci 41, 296–304
(2016). Available at https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4912648/
11. Farsiani, H., Mosavat, A., Soleimanpour, S., Sadeghian, H., Eydgahi, M. R. A., Ghazvini,
K., Sankian, M., Aryan, E., Jamehdar, S. A., Rezaee, S. A.: Fc-based delivery system
enhances immunogenicity of a tuberculosis subunit vaccine candidate consisting of the
ESAT-6:CFP-10 complex. Mol BioSyst 12, 2189–2201 (2016). Available at http://pubs.
rsc.org/-/content/articlelanding/2016/mb/c6mb00174b/unauth#!divAbstract
12. Permyakova, N. V., Zagorskaya, A. A., Belavin, P. A., Uvarova, E. A., Nosareva, O. V.,
Nesterov, A. E., Novikovskaya, A. A., Zav’yalov, E. L., Moshkin, M. P., Deineko, E. V.:
Transgenic carrot expressing fusion protein comprising M. tuberculosis antigens induces
immune response in mice. Biomed Res Int 2015, 417565 (2015). Available at https://www.
hindawi.com/journals/bmri/2015/417565/
56 PERMYAKOVA ET AL.
Acta Microbiologica et Immunologica Hungarica 65, 2018
13. Gupta, U. D., Katoch, V. M.: Animal models of tuberculosis for vaccine development. Indian
J Med Res 129, 11–18 (2009). Available at http://www.ijmr.org.in/article.asp?issn=0971-
5916;year=2009;volume=129;issue=1;spage=11;epage=18;aulast=Gupta;type=0
14. Bradford, M. M.: A rapid and sensitive method for the quantitation of microgram quantities
of protein utilizing the principle of protein-dye binding. Anal Biochem 72, 248–254 (1976).
Available at http://www.sciencedirect.com/science/article/pii/0003269776905273
15. Uﬁmtseva, E.: Investigation of functional activity of cells in granulomatous inﬂammatory
lesions from mice with latent tuberculous infection in the new ex vivo model. Clin Dev
Immunol 2013, 371249 (2013). Available at https://www.hindawi.com/journals/jir/2013/
371249/
16. Clark, S., Hall, Y., Williams, A.: Animal models of tuberculosis: Guinea pigs. Cold Spring
Harb Perspect Med 5, 1–9 (2014). Available at http://perspectivesinmedicine.cshlp.org/
content/5/5/a018572.short
17. Oberg, A. L., Kennedy, R. B., Li, P., Ovsyannikova, I. G., Poland, G. A.: Systems biology
approaches to new vaccine development. Curr Opin Immunol 23, 436–443 (2011).
Available at https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3129601/
18. Day, J., Schlesinger, L. S., Friedman, A.: Tuberculosis research: Going forward with a
powerful ‘Translational Systems Biology’ approach. Tuberculosis 90, 7–8 (2010). Avail-
able at https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2819545/
19. Jacobs, A. J., Mongkolsapaya, J., Screaton, G. R., McShane, H., Wilkinson, R. J.:
Antibodies and tuberculosis. Tuberculosis 101, 102–113 (2016). Available at http://
www.tuberculosisjournal.com/article/S1472-9792(16)30125-1/fulltext
20. Trajkovic, V., Natarajan, K., Sharma, P.: Immunomodulatory action of mycobacterial
secretory proteins. Microbes Infect 6, 513–519 (2004). Available at https://www.ncbi.nlm.
nih.gov/pubmed/15109967
21. Zvi, A., Ariel, N., Fulkerson, J., Sadoff, J. C., Shafferman, A.: Whole genome identiﬁcation
of Mycobacterium tuberculosis vaccine candidates by comprehensive data mining and
bioinformatic analyses. BMC Med Genomics 1, 1–25 (2008). Available at https://bmcmed
genomics.biomedcentral.com/articles/10.1186/1755-8794-1-18
22. Wang, X., Wang, Y., Xue, Y., Chen, Y., Tao, Z., Xia, H., Tang, J., Fang, Q.: Construction,
identiﬁcation and immunoreactivity ofMycobacterium tuberculosis DNA vaccine pVAX1/
ESAT-6 plasmid. Nan Fang Yi Ke Da Xue Xue Bao 33, 945–950 (2013). Available at
https://www.ncbi.nlm.nih.gov/pubmed/23895830
23. Weldingh, K., Andersen, P.: Immunological evaluation of novel Mycobacterium tubercu-
losis culture ﬁltrate proteins. FEMS Immunol Med Microbiol 23, 159–164 (1999).
Available at https://academic.oup.com/femspd/article/23/2/159/514425/Immunological-
evaluation-of-novel-Mycobacterium
24. Renshaw, P. S., Panagiotidou, P., Whelan, A., Gordon, S. V., Hewinson, R. G., Williamson,
R. A., Carr, M. D.: Conclusive evidence that the major T-cell antigens of theMycobacterium
tuberculosis complex ESAT-6 and CFP-10 form a tight, 1:1 complex and characterization
of the structural properties of ESAT-6, CFP-10, and the ESAT-6*CFP-10 complex.
J Biol Chem 277, 21598–21603 (2002). Available at http://www.jbc.org/content/
277/24/21598.short
25. Sreejit, G., Ahmed, A., Parveen, N., Jha, V., Valluri, V. L., Ghosh, S., Mukhopadhyay, S.:
The ESAT-6 protein of Mycobacterium tuberculosis interacts with beta-2-microglobulin
(β2M) affecting antigen presentation function of macrophage. PLoS Pathog 10, 1–10
CFP10–ESAT6–DIFN PROTEIN PROTECTS AGAINST TB 57
Acta Microbiologica et Immunologica Hungarica 65, 2018
(2014). Available at http://journals.plos.org/plospathogens/article?id=10.1371/journal.
ppat.1004446
26. Champion, J. A., Walker, A., Mitragotri, S.: Role of particle size in phagocytosis of
polymeric microspheres. Pharm Res 25, 1815–1821 (2008). Available at https://link.
springer.com/article/10.1007/s11095-008-9562-y
27. Lindblad, E. B.: Aluminium compounds for use in vaccines. Immunol Cell Biol 82, 497–
505 (2004). Available at https://www.ncbi.nlm.nih.gov/pubmed/15479435
28. Karp, C. L., Wilson, C. B., Stuart, L. M.: Tuberculosis vaccines: Barriers and prospects on
the quest for a transformative tool. Immunol Rev 264, 363–381 (2015). Available at http://
onlinelibrary.wiley.com/doi/10.1111/imr.12270/full
29. Olsen, A. W., Williams, A., Okkels, L. M., Hatch, G., Andersen, P.: Protective effect of a
tuberculosis subunit vaccine based on a fusion of antigen 85B and ESAT-6 in the aerosol
guinea pig model. Infect Immun 72, 6148–6150 (2004). Available at http://iai.asm.org/
content/72/10/6148.short
30. Skeiky, Y. W., Alderson, M. R., Ovendale, P. J., Guderian, J., Brandt, L., Dillon, D. C.,
Campos-Neto, A., Lobet, Y., Dalemans, W., Orme, I. M., Reed, S. G.: Differential immune
responses and protective efﬁcacy induced by components of a tuberculosis polyprotein
vaccine, Mtb72F, delivered as naked DNA or recombinant protein. J Immunol 172, 7618–
7628 (2004). Available at http://www.jimmunol.org/content/172/12/7618.short
31. Liu, X., Peng, J., Hu, L., Luo, Y., Niu, H., Bai, C., Wang, Q., Li, F., Yu, H., Wang, B.,
Chen, H., Guo, M., Zhu, B.: A multistage Mycobacterium tuberculosis subunit vaccine
LT70 including latency antigen Rv2626c induces long-term protection against tuberculosis.
Hum Vaccines Immunother 12, 1670–1677 (2016). Available at http://www.tandfonline.
com/doi/abs/10.1080/21645515.2016.1141159
58 PERMYAKOVA ET AL.
Acta Microbiologica et Immunologica Hungarica 65, 2018
